1. Efflux pumps: Fungi can develop increased expression of efflux pumps, which are proteins that actively pump antifungal drugs out of the fungal cell. This reduces the intracellular concentration of the drug, making it less effective.
2. Target site modification: Mutations in the target sites of antifungal drugs can alter their binding affinity or enzymatic activity, reducing the drug's effectiveness. For example, mutations in the ergosterol synthesis pathway, which is targeted by azole antifungals, can confer resistance to these drugs.
3. Enhanced metabolic pathways: Some fungi can develop enhanced metabolic pathways that allow them to bypass the action of antifungal drugs. For instance, *C. auris* has been found to have increased activity of an enzyme called Cdr1p, which metabolizes and detoxifies azole drugs.
4. Biofilm formation: Fungi can form biofilms, which are communities of cells that adhere to surfaces and are encased in a protective matrix. Biofilms can limit the penetration of antifungal drugs, contributing to drug resistance.
5. Horizontal gene transfer: Fungi can acquire resistance genes from other microorganisms through horizontal gene transfer. This process involves the transfer of genetic material between different organisms, potentially facilitating the spread of resistance traits among fungal populations.
6. Efflux Pumps Inhibition: Mutations that inhibit the expression or function of efflux pumps make it harder for the fungal cells to pump out the drugs, thus increasing the intracellular drug concentration and restoring drug efficacy.
It's important to note that drug resistance can vary among different fungal species and strains. Understanding the mechanisms of drug resistance in fungi is crucial for developing effective strategies to combat and prevent the spread of antifungal resistance. Continuous research, surveillance, and proper antifungal stewardship practices are essential for managing and mitigating the threat of drug resistance in *C. auris* and other fungi.
